223
Views
0
CrossRef citations to date
0
Altmetric
Erratum

Erratum

Pages 313-314 | Published online: 09 Jan 2014
Figure 1. Mean plasma concentration–time curves at steady state for paroxetine IR 20 mg and paroxetine CR 25 mg.

Results from two separate studies 419 and 564. Adapted from [76]. CR: Controlled release; IR: Immediate release.

Figure 1. Mean plasma concentration–time curves at steady state for paroxetine IR 20 mg and paroxetine CR 25 mg.Results from two separate studies 419 and 564. Adapted from [76]. CR: Controlled release; IR: Immediate release.
Figure 2. Likelihood of being compliant when compared with paroxetine controlled-release, controlling for age, gender, utilization of psychiatric specialty services, titration rates and the comorbidity measures.

IR: Immediate release. Adapted from [94].

Figure 2. Likelihood of being compliant when compared with paroxetine controlled-release, controlling for age, gender, utilization of psychiatric specialty services, titration rates and the comorbidity measures.IR: Immediate release. Adapted from [94].
Figure 1. Mean plasma concentration–time curves at steady state for paroxetine IR 20 mg and paroxetine CR 25 mg.

Results from two separate studies 419 and 564. Adapted from [69]. CR: Controlled release; IR: Immediate release.

Figure 1. Mean plasma concentration–time curves at steady state for paroxetine IR 20 mg and paroxetine CR 25 mg.Results from two separate studies 419 and 564. Adapted from [69]. CR: Controlled release; IR: Immediate release.
Figure 2. Likelihood of being compliant when compared with paroxetine controlled-release, controlling for age, gender, utilization of psychiatric specialty services, titration rates and the comorbidity measures.

IR: Immediate release. Adapted from [87].

Figure 2. Likelihood of being compliant when compared with paroxetine controlled-release, controlling for age, gender, utilization of psychiatric specialty services, titration rates and the comorbidity measures.IR: Immediate release. Adapted from [87].

In the review by Chi-Un Pae and Ashwin A Patkar, Paroxetine: current status in psychiatry, published in the February 2007 issue of Expert Review of Neurotherapeutics (Expert Rev. Neurotherapeutics 7[2], 107–120 [2007]), the original text on page 111 reads:

GlaxoSmithKline’s recent letter to doctors points to a sixfold increase in the risk of suicidal behavior in adults taking paroxetine [104]; 32% (11 out of 3455) treated with paroxetine attempted suicide compared with 0.05% (one out of 1978) treated with placebo (OR: 6.7; 95% CI: 1.1–149.4).

The following figures on pages 112 and 115, respectively, show:

The corrected text should read:

GlaxoSmithKline’s recent letter to doctors points to a sixfold increase in the risk of suicidal behavior in adults taking paroxetine [104]; 0.32% (11 out of 3455) treated with paroxetine attempted suicide compared with 0.05% (one out of 1978) treated with placebo (OR: 6.7; 95% CI: 1.1–149.4).

The correct figures are given below:

The editors of Expert Review of Neurotherapeutics would like to sincerely apologize for any inconvenience or confusion the numbering error in this figure footnote may cause our readers.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.